Accession Therapeutics Limited
Emily Trimby is a Senior Scientist at Accession Therapeutics Limited since October 2024, previously holding the same title at Akamis Bio from March 2020 to October 2024, where Emily also progressed through Scientist I and Scientist II roles. Prior experience includes a position as a Research Assistant at Evotec from February 2015 to March 2020 and a year as a Trainee Biomedical Scientist at Calderdale and Huddersfield NHS Foundation Trust. Emily also served as a Language Assistant at La Salle Horta, helping to develop conversational English skills in Spanish children. Emily earned an Undergraduate Master's Degree in Biomedical Sciences from the University of Hull between 2009 and 2013.
This person is not in any teams
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.